Lexeo Therapeutics (LXEO) News Today $8.50 +0.30 (+3.66%) Closing price 04:00 PM EasternExtended Trading$8.42 -0.08 (-0.94%) As of 07:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock LXEO Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Moderate Buy" from AnalystsOctober 14 at 4:11 AM | marketbeat.comLeerink Partnrs Has Optimistic Outlook of LXEO Q3 EarningsOctober 12 at 2:11 AM | americanbankingnews.comQ3 EPS Estimate for Lexeo Therapeutics Raised by AnalystOctober 11 at 6:56 AM | marketbeat.comLexeo Therapeutics (NASDAQ:LXEO) Earns "Sell (D-)" Rating from Weiss RatingsOctober 10, 2025 | marketbeat.comHC Wainwright & Co. Maintains Lexeo Therapeutics (LXEO) Buy RecommendationOctober 8, 2025 | msn.comLeerink Partners Maintains Lexeo Therapeutics (LXEO) Outperform RecommendationOctober 8, 2025 | msn.comLexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval ProcessOctober 7, 2025 | msn.comLexeo Therapeutics stock soars after FDA accelerated approval progressOctober 7, 2025 | investing.comLexeo climbs after regulatory update on Friedreich ataxia drugOctober 7, 2025 | msn.comLexeo Therapeutics Shares Surge 25% on FDA Accelerated Approval Pathway ProgressOctober 7, 2025 | msn.comLexeo: Maintaining Buy Rating Based On FDA Accelerated Approval FeedbackOctober 7, 2025 | seekingalpha.comLexeo Therapeutics, Inc. - Special CallOctober 7, 2025 | seekingalpha.comLexeo Therapeutics (NASDAQ:LXEO) Price Target Raised to $20.00October 7, 2025 | marketbeat.comLexeo Therapeutics Advances FDA Discussions for LX2006October 7, 2025 | tipranks.comLexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia CardiomyopathyOctober 7, 2025 | globenewswire.comPalumbo Wealth Management LLC Invests $226,000 in Lexeo Therapeutics, Inc. $LXEOSeptember 26, 2025 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of "Buy" from BrokeragesSeptember 19, 2025 | marketbeat.comLexeo Therapeutics, Inc. $LXEO Shares Sold by Adage Capital Partners GP L.L.C.September 10, 2025 | marketbeat.comVestal Point Capital LP Cuts Stock Position in Lexeo Therapeutics, Inc. $LXEOSeptember 4, 2025 | marketbeat.comIs Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Invest In Growth?August 29, 2025 | finance.yahoo.comAffinity Asset Advisors LLC Acquires Shares of 1,480,881 Lexeo Therapeutics, Inc. $LXEOAugust 28, 2025 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Buy" from AnalystsAugust 27, 2025 | marketbeat.comWhat is Chardan Capital's Forecast for LXEO FY2025 Earnings?August 23, 2025 | marketbeat.comInsider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells 2,735 Shares of StockAugust 21, 2025 | insidertrades.comLexeo Therapeutics’ Friedreich Ataxia Gene Therapy Receives FDA Breakthrough Therapy DesignationAugust 20, 2025 | msn.comLexeo Therapeutics (NASDAQ:LXEO) Given New $15.00 Price Target at Chardan CapitalAugust 17, 2025 | marketbeat.comLexeo Therapeutics (NASDAQ:LXEO) Announces Earnings ResultsAugust 17, 2025 | marketbeat.comLexeo Therapeutics (NASDAQ:LXEO) Given New $9.00 Price Target at HC WainwrightAugust 17, 2025 | marketbeat.comLexeo Therapeutics price target lowered to $15 from $20 at ChardanAugust 16, 2025 | msn.comLexeo Therapeutics reports Q2 EPS (60c) vs (64c) last yearAugust 14, 2025 | msn.comLexeo Therapeutics Appoints New Chief Financial OfficerAugust 14, 2025 | tipranks.comLexeo Therapeutics Reports Second Quarter 2025 Financial Results and Operational HighlightsAugust 14, 2025 | globenewswire.comLexeo Therapeutics (NASDAQ:LXEO) Shares Up 1.8% - What's Next?August 10, 2025 | marketbeat.comLexeo Therapeutics (LXEO) Projected to Post Quarterly Earnings on MondayAugust 5, 2025 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Recommendation of "Buy" from BrokeragesAugust 1, 2025 | marketbeat.comLexeo Therapeutics (NASDAQ:LXEO) Coverage Initiated by Analysts at OppenheimerAugust 1, 2025 | marketbeat.comOppenheimer Initiates Coverage of Lexeo Therapeutics (LXEO) with Outperform RecommendationAugust 1, 2025 | msn.comStifel Maintains Buy Rating on Lexeo Therapeutics (LXEO)July 29, 2025 | msn.comLexeo Therapeutics Holds 2025 Annual Stockholders MeetingJuly 25, 2025 | theglobeandmail.comLexeo Therapeutics (NASDAQ:LXEO) Shares Up 3.6% - Still a Buy?July 10, 2025 | marketbeat.comLexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia - MorningstarJuly 8, 2025 | morningstar.comMLexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich Ataxia Treatment - NasdaqJuly 8, 2025 | nasdaq.comWhy Lexeo Is Rising In Pre-market? - NasdaqJuly 8, 2025 | nasdaq.comLexeo Therapeutics stock rises after FDA breakthrough designationJuly 8, 2025 | au.investing.comLexeo Therapeutics Shares Climb Following FDA Breakthrough Therapy DesignationJuly 8, 2025 | msn.comLexeo Therapeutics Announces FDA Breakthrough Therapy Designation for LX2006 in Friedreich AtaxiaJuly 7, 2025 | globenewswire.comLexeo Therapeutics stockholders elect directors and ratify auditor at annual meeting - Investing.comJuly 2, 2025 | investing.comLexeo Therapeutics, Perceptive Xontogeny Venture Funds and venBio Partners Announce Partnership to Advance Novel Cardiac RNA TherapeuticsJune 24, 2025 | globenewswire.comLexeo Therapeutics files to sell 41.63M shares of common stock for holdersJune 13, 2025 | msn.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Shares Acquired by Millennium Management LLCJune 6, 2025 | marketbeat.com Get Lexeo Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for LXEO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. LXEO Media Mentions By Week LXEO Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. LXEO News Sentiment▼0.720.72▲Average Medical News Sentiment LXEO News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. LXEO Articles This Week▼133▲LXEO Articles Average Week Get the Latest News and Ratings for LXEO and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Lexeo Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Evotec News Today Arcus Biosciences News Today Stoke Therapeutics News Today LENZ Therapeutics News Today Syndax Pharmaceuticals News Today Sionna Therapeutics News Today Xeris Biopharma News Today Taysha Gene Therapies News Today Zymeworks News Today Nuvation Bio News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:LXEO) was last updated on 10/14/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredRobinhood warningA strange chasm is coming to Wall Street... It's already creating millionaires and billionaires at the fast...Stansberry Research | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredOptions Pro Reveals His #1 Retirement Income TradeIf you want a way to generate consistent market income without chasing volatile AI stocks or complex crypto tr...Base Camp Trading | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lexeo Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Lexeo Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
